Skip to main content
SpringerLink
Log in

The first meeting of the Austrian Expert Panel for Molecular Cancer Profiling

Current status of multiplex molecular profiling and precision oncology in Austria

  • special report
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Personalized medicine is rapidly changing the daily routine for the diagnostic work-up and treatment of cancer patients. Several clinical studies and programs are ongoing worldwide to implement personalized anticancer therapies particularly for relapsed/refractory malignancies. On 28 October 2016, the first meeting of the Austrian Expert Panel for Molecular Cancer Profiling was held in Salzburg with the purpose to identify clinical studies and registry programs focusing on comprehensive molecular tumor profiling and personalized cancer therapies in Austria. Representatives of the four Austrian academic centers and from two teaching hospitals were invited to present and debate the current status, challenges, and perspectives in precision oncology. To date, three clinical programs are recruiting patients with relapsed/refractory malignancies in Austria: the ONCO-T-PROFILE program at the Medical University of Innsbruck, the platform MONDTI at the Medical University of Vienna, and the ICT (Individualized Cancer Treatment) phase II trial at the Medical University of Graz. The aim of both research programs and the phase II trial is to investigate the efficacy of molecular profile-based personalized therapies in refractory and relapsed metastatic cancer patients. Furthermore, in cooperation with the AGMT (Study Group of Medical Tumor Therapy), a clinical registry will be established to monitor and to analyze the benefit of molecular profiling in real life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–52.

    Article  CAS  PubMed  Google Scholar 

  2. Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2017; https://doi.org/10.1200/JCO.2017.74.7576.

    Google Scholar 

  3. Li G, Dai WR, Shao FC. Effect of ALK-inhibitors in the treatment of non-small cell lung cancer: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2017;21:3496–503.

    CAS  PubMed  Google Scholar 

  4. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963–71.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Shaw AT, Kim TM, Crinò L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18:874–86.

    Article  CAS  PubMed  Google Scholar 

  6. Park JW, Liu MC, Yee D, et al. Adaptive randomization of Neratinib in early breast cancer. N Engl J Med. 2016;375:11–22.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Gianni L, Pienkowski T, Im YH, et al. 5‑year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17:791–800.

    Article  CAS  PubMed  Google Scholar 

  8. Dahabreh IJ, Linardou H, Siannis F, et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist. 2008;13:620–30.

    Article  CAS  PubMed  Google Scholar 

  9. Martin M, López-Tarruella S. Emerging therapeutic options for HER2-positive breast cancer. Am Soc Clin Oncol Educ Book. 2016;35:e64–e70.

    Article  PubMed  Google Scholar 

  10. Moasser MM, Krop IE. The evolving landscape of HER2 targeting in breast cancer. JAMA Oncol. 2015;1(8):1154–61.

    Article  PubMed  Google Scholar 

  11. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11(10):685–96.

    Article  CAS  PubMed  Google Scholar 

  12. McDermott U. Next-generation sequencing and empowering personalised cancer medicine. Drug Discov Today. 2015;20(12):1470–5.

    Article  PubMed  Google Scholar 

  13. Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108–12.

    Article  CAS  PubMed  Google Scholar 

  14. Carpinetti P, Donnard E, Bettoni F, et al. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation. Oncotarget. 2015;6(35):38360–71.

    Article  PubMed Central  PubMed  Google Scholar 

  15. André F, Bachelot T, Commo F, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 2014;15(3):267–74.

    Article  PubMed  Google Scholar 

  16. Massard C, Michiels S, Ferté C, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586–95.

    Article  CAS  PubMed  Google Scholar 

  17. Schwaederle M, Zhao M, Lee JJ, et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol. 2016;2(11):1452–9.

    Article  PubMed  Google Scholar 

  18. Seeber A, Gastl G, Ensinger C, et al. Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project. Genes Cancer. 2016;7(9–10):301–8.

    PubMed Central  PubMed  Google Scholar 

  19. Caswell DR, Swanton C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med. 2017;15(1):133.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Esposito A, Criscitiello C, Locatelli M, et al. Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. Pharmacol Ther. 2016;157:120–4.

    Article  CAS  PubMed  Google Scholar 

  21. Mantovani F, Walerych D, Sal GD. Targeting mutant p53 in cancer: a long road to precision therapy. FEBS J. 2017;284(6):837–50.

    Article  CAS  PubMed  Google Scholar 

  22. Matikas A, Mistriotis D, Georgoulias V, et al. Targeting KRAS mutated non-small cell lung cancer: a history of failures and a future of hope for a diverse entity. Crit Rev Oncol Hematol. 2017;110:1–12.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department for Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria

    Andreas Seeber MD, PhD, Günther Gastl & Gerold Untergasser

  2. Department for Internal Medicine and Oncology, County Hospital of Klagenfurt, Klagenfurt, Austria

    Wolfgang Eisterer

  3. Department for Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg, Austria

    Simon P. Gampenrieder & Richard Greil

  4. Division of Clinical Oncology, Medical University of Graz, Graz, Austria

    Armin Gerger & Martin Pichler

  5. Department of Internal Medicine I, Medical University Vienna, Vienna, Austria

    Markus Kieler & Gerald W. Prager

  6. Department for Internal Medicine I, Ordensklinikum Linz, Linz, Austria

    Ansgar Weltermann

  7. Salzburg Cancer Research Institute, Salzburg, Austria

    Simon P. Gampenrieder & Richard Greil

  8. Cancer Cluster Salzburg, Salzburg, Austria

    Simon P. Gampenrieder & Richard Greil

  9. Arbeitsgemeinscchaft Medikamentöse Tumortherapie (AGMT), Salzburg, Austria

    Simon P. Gampenrieder & Richard Greil

Authors
  1. Andreas Seeber MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Günther Gastl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wolfgang Eisterer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Simon P. Gampenrieder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Armin Gerger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Markus Kieler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Martin Pichler
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gerald W. Prager
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gerold Untergasser
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ansgar Weltermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Richard Greil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Seeber MD, PhD.

Ethics declarations

Conflict of interest

A. Seeber and G. Gastl served as consultant for Caris Life Sciences. W. Eisterer, S. Gampenrieder, A. Gerger, M. Kieler, M. Pichler, G.W. Prager, G. Untergasser, A. Weltermann, and R. Greil declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seeber, A., Gastl, G., Eisterer, W. et al. The first meeting of the Austrian Expert Panel for Molecular Cancer Profiling. memo 10, 255–258 (2017). https://doi.org/10.1007/s12254-017-0369-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-017-0369-6

Keywords

Search

Navigation